Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13651 - 13675 of 14615 in total
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
Investigational
Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Investigational
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Investigational
Matched Description: … It was developed for the treatment and prevention of thromboembolic events. …
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Hydronidone has antifibrotic activity.
Investigational
Displaying drugs 13651 - 13675 of 14615 in total